The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 28, 2022

Filed:

Jun. 23, 2017
Applicant:

Novo Nordisk A/s, Bagsvaerd, DK;

Inventors:

Tinna Bjoerk Aradottir, Copenhagen, DK;

Henrik Bengtsson, Taastrup, DK;

Pete Brockmeier, Copenhagen V, DK;

Assignee:

Novo Nordisk A/S, Bagsvaerd, DK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16H 20/17 (2018.01); A61B 5/145 (2006.01); G16H 40/63 (2018.01); G16H 50/30 (2018.01); A61B 5/00 (2006.01); G16H 50/20 (2018.01); A61M 5/20 (2006.01);
U.S. Cl.
CPC ...
G16H 20/17 (2018.01); A61B 5/0022 (2013.01); A61B 5/14532 (2013.01); A61B 5/4839 (2013.01); A61B 5/7275 (2013.01); A61M 5/20 (2013.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); A61M 2005/2093 (2013.01); A61M 2205/3306 (2013.01); A61M 2205/3592 (2013.01); A61M 2205/50 (2013.01); A61M 2205/52 (2013.01); A61M 2205/581 (2013.01); A61M 2205/6054 (2013.01); A61M 2230/005 (2013.01); A61M 2230/201 (2013.01); A61M 2230/50 (2013.01);
Abstract

Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject and insulin injection data is obtained. A first glycaemic risk measures is determined, where the first risk glycaemic risk measure is i) glucose level variability across the glucose measurements, (ii) a variability in fasting glucose levels calculated from the glucose measurements, (iii) a minimum observed glucose measurement in the plurality of glucose measurements (iv) rate of change in ISF, or (v) adherence values. A fasting blood glucose target function is computed based upon at least the first glycaemic risk measure thereby obtaining an updated target fasting blood glucose level that is between a minimum and maximum target fasting blood glucose level. The long acting insulin medicament dosage is adjusted based upon the updated target fasting blood glucose level.


Find Patent Forward Citations

Loading…